DMD

Monthly Dosing Of Sarepta's Next-Gen Eteplirsen Can Potentially Achieve Over 10% Higher Dystrophin Expression In DMD Patients

Solid Biosciences Rips Higher On Positive Biomarker Data For DMD Drug

Why Wave Life Sciences's Valuation Is Falling By 25% (NASDAQ:WVE)

Solid Biosciences Rips Higher On Positive Biomarker Data For DMD Drug

Why Wave Life Sciences's Valuation Is Falling By 25% (NASDAQ:WVE)

Analyst: Sarepta's DMD Gene Therapy Results 'Dramatic And Far Exceeding Expectations'

Summit Therapeutics' Upcoming Duchenne Muscular Dystrophy Data 'A Strong Catalyst,' Janney Says In Bullish Initiation

Analyst: Sarepta's DMD Gene Therapy Results 'Dramatic And Far Exceeding Expectations'

Summit Therapeutics' Upcoming Duchenne Muscular Dystrophy Data 'A Strong Catalyst,' Janney Says In Bullish Initiation

Goldman Sachs Gets Firm On Solid Biosciences

Sarepta Marks A 'Very Important Day' For The DMD Community

DMD Recent News

Down 16% Over May, Has Sarepta Become A Cheap Takeout Target?

Sarepta Under Pressure As FDA Approves Marathon Pharma's Emflaza For DMD Treatment

Sarepta Under Pressure Amid Concerning Exondys 51 Survey Results

For Sapreta, Today's Good News Might Be Just The Beginning

Sarepta Soars Following Encouraging Exondys 51 News

Credit Suisse Says Sarepta Shares Volatile, Still A Favorite Idea

2 Opposing Views On The Future Of Sarepta

The Rise And Fall Of Sarepta's Stock Since Exondys 51 Accelerated Approval

New Aetna Clinical Policy Bulletin Details 'Medical Necessity' Of Sarepta's Exondys 51

Aetna Still Undecided On Coverage For Sarepta's Highly Debated Muscular Dystrophy Treatment

A Timeline Of PTC Therapeutics' Translarna Journey

3 Reasons 2017 Launch Expectations For Sarepta's EXONDYS 51 Are 'Too High'

PTC Therapeutics Surges 88% On European Marketing Authorization

Sarepta Shares Fall After Anthem Blue Cross Finds Issue With Eteplirsen

DMD Deal With Summit Is 'Low Risk, High Reward' For Sarepta

Sarepta Wins Exclusive License, Collaboration Deal for European Rights To Summit's DMD Drug

Sarepta Dosing First Patients In Phase 3 Trial Of Duchenne Muscular Dystrophy Drug

FDA Commish Says Sarepta's DMD Study Should Be Retracted

Sarepta Prices Newly-Approved DMD Drug, Cowen Upgrades Stock To Outperform

Sarepta Analysts Turn Bullish After Duchenne Muscular Dystrophy Drug Eteplirsen Gets Approval

PTC Therapeutics Gets Big Boost From Sarepta's DMD Drug Approval

Sarepta Spikes 20%, Feuerstein Says Company Can Win FDA Drug Approval

Sarepta Therapeutics Dropped 10% Following FDA News